

Review

Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment

Ming-Ming Chen,* Jing-Jing Cai,† Yao Yu,‡ Zhi-Gang She,*‡§¶ and Hongliang Li*‡§¶

*Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, P.R. China

†Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, P.R. China

‡Institute of Model Animals of Wuhan University, Wuhan, P.R. China

§Basic Medical School, Wuhan University, Wuhan, P.R. China

¶Medical Research Institute, School of Medicine, Wuhan University, Wuhan, P.R. China

Nonalcoholic steatohepatitis (NASH) is the second leading cause of liver transplantation in the US with a high risk of liver-related morbidities and mortality. Given the global burden of NASH, development of appropriate therapeutic strategies is an important clinical need. Where applicable, lifestyle modification remains the primary recommendation for the treatment of NASH, even though such changes are difficult to sustain and even insufficient to cure NASH. Bariatric surgery resolves NASH in such patients where lifestyle modifications have failed, and is recommended for morbidly obese patients with NASH. Thus, pharmacotherapies are of high value for NASH treatment. Though no drug has been approved by the US Food and Drug Administration for treatment of NASH, substantial progress in pharmacological development has been made in the last few years. Agents such as vitamin E and pioglitazone are recommended in patients with NASH, and yet concerns about their side effects remain. Many agents targeting various vital molecules and pathways, including those impacting metabolic perturbations, inflammatory cascades, and oxidative stress, are in clinical trials for the treatment of NASH. Some agents have shown promising results in phase II or III clinical trials, but more studies are required to assess their long-term effects. Herein, we review the potential strategies and challenges in therapeutic approaches to treating NASH.

Key words: Nonalcoholic steatohepatitis (NASH); Pharmacological therapy; Molecular targets; Lifestyle modification; Bariatric surgery

INTRODUCTION

Nonalcoholic fatty liver disease (NAFLD), which is a clinicopathological spectra of liver diseases including simple steatosis, nonalcoholic steatohepatitis (NASH), and cirrhosis, has become a major cause of chronic liver disease in adults¹. NASH is characterized by steatosis, lobular inflammation, and hepatocellular ballooning and can potentially progress to cirrhosis^{2,3}. It is the second leading cause of liver transplantation in the US with a high risk of liver-related morbidity and mortality^{4,5}. At present, the global prevalence rate of NAFLD is approximately 25%, while the prevalence of NASH in general people is estimated to be 3%–5% worldwide^{6,7}. NASH is highly related to obesity, dyslipidemia, and type 2

diabetes⁷. Due to the growing prevalence of obesity, the incidence of NASH may increase further. The high incidence and the poor clinical outcomes of NASH thus are being viewed as a serious global burden.

No US Food and Drug Administration (FDA)-approved medication currently exists for NASH⁸. Some available strategies, including lifestyle modification, bariatric surgery, and pharmacological therapies, have been recommended for the treatment of NASH in eligible and appropriate patients. The currently recommended treatments have their limitations, so new medical treatments are needed. To date, several novel therapies targeting different stages of NASH pathogenesis, including metabolic perturbations, inflammatory cascades, and oxidative stress, have entered clinical trials (Fig. 1). In addition, it is

Address correspondence to Hongliang Li, M.D., Ph.D., Department of Cardiology, Renmin Hospital of Wuhan University, No. 99 Zhangzhidong Road, Wuchang District, Wuhan 430071, Hubei, P.R. China. Tel/Fax: 86-27-68759302; E-mail: lihl@whu.edu.cn




Figure 1. Core mechanisms of therapeutic targets for nonalcoholic steatohepatitis (NASH). (1) Agents that target metabolic homeostasis in the liver. This group includes ACC inhibitors, FXR agonists, FGF 19/21 analog, PPAR agonist, THR agonists, SCD1 inhibitor, GLP-1 receptor agonist. (2) Agents that target inflammatory cascade and oxidative stress. This group includes vitamin E, CCR2/5 antagonist, TLR4 antagonist, ASK1 inhibition, galectin-3 inhibitor, and caspase inhibitor. Some therapeutic pathways (orange box) broadly regulate metabolic pathways. Other therapeutic pathways (blue box) regulate inflammatory cascade and oxidative stress. The blue circles indicate therapeutic targets. PPAR, peroxisome proliferator-activated receptor; TCA, tricarboxylic acid; ACC, acetyl-CoA carboxylase; FFA, free fatty acid; SCD1, stearyl coenzyme a desaturase 1; TNF, tumor necrosis factor; FGF21, fibroblast growth factor 21; SREBP, sterol regulatory element-binding proteins; PCSK9, proprotein convertase subtilisin/kexin 9; THR, thyroid hormone receptor; FGF19, fibroblast growth factor 19; SHP, small heterodimer partner; FXR, farnesoid X receptor; RXR, retinoid-x receptor; FXRE, farnesoid X receptor element; TGR5, Takeda G protein-coupled receptor 5; GLP-1, glucagon-like peptide 1; ASK1, apoptosis signal-regulating kinase 1; CCR, C-C motif chemokine receptor; TLR4, toll-like receptor 4; LPS, lipopolysaccharide.

exciting that animal studies along with subsequent clinical trials have shown some promising results. This review discusses up-to-date therapies that have been developed to treat NASH and are mainly in phase II or III trials and their pharmacologic targets, in hopes of bringing new insights into the mechanisms and treatment of NASH.

CURRENTLY RECOMMENDED THERAPIES

Lifestyle Modification

Lifestyle modification has represented the cornerstone of therapies for patients with NASH and includes weight loss, diet, and exercise. A comprehensive lifestyle

intervention that includes reduced calorie intake and increased exercise can improve the histological features of NASH⁹.

Weight Loss

Modest weight loss reduced inflammation and altered homeostasis in humans, shedding light on its potential value for treating NASH¹⁰. The amount of weight loss is a determining factor in improving histological features of NASH patients. Specifically, weight reduction of 3%–5% is helpful for improving steatosis, while reductions of 5%–7% are necessary for attenuating inflammation^{11,12}.

Significant weight loss of 7% or more may improve the histologic features of NASH, involving hepatic steatosis, ballooning, and lobular inflammation^{13–15}, while weight reductions of 10% are required to improve fibrosis and portal inflammation, as exhibited in a prospective trial¹¹. Unfortunately, more than half of the subjects fail to achieve the goal of losing 7% of body weight at 12 months in the same study, underscoring the challenges of lifestyle modifications as a universal and practical intervention for NASH.

Diet

A dietary fat with saturated fatty acids is associated with the development of NASH, but *n*–3 polyunsaturated fatty acids have protective effects on NASH by mitigating hepatic oxidative stress and inflammation^{16,17}. Recently, the Mediterranean diet, identified as a low-fat and restricted-calorie diet with ample *n*–3 polyunsaturated fatty acids, has been demonstrated to reduce hepatic fat and improve hepatic insulin sensitivity, and adherence to the Mediterranean diet lower the risk for NASH. Moreover, this diet is recommended by the EASL-EASD-EASO Clinical Practice Guidelines^{18–20}. Fructose intake should be limited in patients with NASH because its consumption was associated with NASH²¹. In addition, some dietary supplements contribute to the treatment of NASH, such as coffee and probiotics^{22–24}.

Exercise

Exercise is beneficial for improving liver fat and histology of NASH^{25,26}. Different forms of exercise have similar beneficial effects on hepatic fat, and vigorous exercise has the largest effects on NASH and fibrosis⁹. However, these effects disappear if patients do not exercise persistently. Vigorous exercise of no less than 250 min/week mitigates the pathophysiology of NASH better than exercise of less than 250 min/week, but excessive exercise is harmful for patients with cardiovascular complications¹². Moderate intensity aerobic exercise over three to five sessions for 150–200 min/week is recommended by the EASL-EASD-EASO guidelines¹⁸. More studies on exercise are needed to verify its long-term effects on NASH and the related morbidity and mortality.

Although lifestyle modifications are considered generally safe, rapid weight loss achieved by any modality may increase the risk of cholelithiasis because of the increase in cholesterol flux through the biliary system, and many patients may experience problems regarding steadfast adherence²⁷.

Bariatric Surgery

Bariatric surgery is an effective way to obtain long-term weight loss. Bariatric surgery prevented NASH progression in diet-induced obese rats of an animal research²⁸,

and the current evidence has demonstrated that liver steatosis, inflammation, and fibrosis were improved in NASH patients after bariatric surgery^{29,30}. What is more, a recent study indicated that bariatric surgery has a long-term effect of mitigating NASH, and the effect could last for 10 years after various bariatric surgeries³¹. Bariatric surgery is applicable in morbidly obese patients with NASH and post-liver transplantation recurrent NASH³². However, insufficient clinical data exist to recommend bariatric surgery as a routine treatment for NASH considering the perioperative risks and cost effectiveness²⁹. Larger randomized controlled trials (RCT) should be designed to confirm the efficacy and safety of bariatric surgery on NASH.

Pharmacological Therapy

Pharmacotherapies should be considered for NASH and fibrosis patients due to the limitations of lifestyle modification and bariatric surgery. Vitamin E and pioglitazone have been suggested as pharmacotherapies for histologically confirmed NASH patients in guidelines from the US, Europe, China, and Japan.

Vitamin E

Currently, vitamin E is the accepted first-line pharmacological treatment for NASH in nondiabetic patients. Vitamin E is an essential antioxidant that acts by inhibiting lipid peroxidation and improving lipid metabolism. In mouse models of NASH, vitamin E attenuated lipid peroxidation and inflammatory responses³³. The potential effect of vitamin E on NASH has been evaluated in four clinical trials of which the PIVENS trial (Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis) is the largest RCT^{34–37}. In the PIVENS trial, 247 subjects with histologically confirmed NASH were randomly assigned to receive pioglitazone 30 mg/day (80 patients), vitamin E 800 IU/day (84 patients), or placebo (83 patients) for 96 weeks³⁷. Vitamin E was superior to the placebo in improving alanine transaminase (ALT) levels, liver steatosis, and inflammation but did not significantly mitigate fibrosis. The long-term safety of vitamin E has been controversial, so its benefits need to be weighed against the increased risks of prostate cancer, hemorrhagic stroke, and even all-cause mortality³⁸.

Pioglitazone

Peroxisome proliferator-activated receptors (PPARs), including PPAR α , β , and γ , are nuclear receptors involved in lipid metabolism. Pioglitazone, a PPAR γ agonist, regulates plasma adiponectin and improves insulin sensitivity in the liver³⁹. It could improve histologic alterations including hepatic injury and fibrosis in patients with NASH⁴⁰. The function of alleviating histological components was

also verified in the PIVENS trial, but this efficacy did not reach the predicted threshold³⁷. It did resolve steatohepatitis in a subset of patients. A similar long-term RCT involving 101 prediabetic and diabetic patients with biopsy-proven NASH showed that pioglitazone treatment improved all histologic features and ameliorated NASH without a worsening of fibrosis⁴¹. Pioglitazone should be used carefully for NASH in diabetic patients with potential long-term risk concerns.

Some drugs such as statins, metformin, and lipase inhibitors seem to be safe but are not recommended because no histological data are available to support their effects on NASH. More novel pharmacological approaches are necessary for treating NASH because the long-term safety and impact on currently recommended pharmacotherapies should be further evaluated.

PROMISING MOLECULAR TARGETS FOR PHARMACOLOGICAL THERAPY

Some pharmacological therapies with different targets, including those impacting metabolic perturbations, inflammatory cascades, and oxidative stress, and are in phase II or III trials are promising for the treatment of NASH. Recently completed and ongoing RCTs for NASH are summarized in Table 1.

Targeting Metabolic Perturbations

Acetyl-CoA Carboxylase (ACC) Inhibitors. ACC regulates the nonreversible conversion of acetyl-CoA to malonyl-CoA and includes the isoforms ACC1 and ACC2⁴². Malonyl-CoA regulates fatty acid synthesis, which is a hallmark of various metabolic diseases including NASH. At present, several ACC inhibitors have shown beneficial effects in preclinical studies and clinical trials of NASH. Notably, GS-0976, an inhibitor of ACC1 and ACC2, decreased liver steatosis, markers of liver injury, and de novo lipogenesis (DNL) in a placebo-controlled trial of NASH patients⁴³. ND-630, an isozyme-nonselective ACC inhibitor, can reduce fatty acid synthesis and promote fatty acid oxidation in cultured cells and animals. In animal models, ND-630 decreased liver steatosis, improved insulin sensitivity, as well as modulated dyslipidemia⁴⁴. However, no clinical trial has tested the effect and safety of ND-630 in NASH patients. MK-4074, a liver-targeting inhibitor of ACC1 and ACC2, reduced hepatic triglyceride (TG) levels in preclinical studies and significantly reduced liver fat in human beings⁴⁵. Unfortunately, the use of ACC inhibitors can increase the expression of glycerol-3-phosphate acyltransferase 1, which plays an important part in mediating triglyceride synthesis, ultimately leading to significant hypertriglyceridemia⁴⁵.

Farnesoid X Receptor (FXR) Agonists. FXR was initially identified as a bile acid sensor that controls bile acid and lipid homeostasis through the small heterodimer

partner (SHP)^{46,47}. Obeticholic acid (OCA), an agonist of FXR, improves insulin sensitivity, inflammation, and fibrosis and reduces hepatic steatosis in obese rats⁴⁸. In a recent clinical trial (FLINT), OCA induced a definite improvement in NASH activity, serum aminotransferase, and fibrosis score compared with placebo⁴⁹. Furthermore, in a phase II study, OCA administered to NASH patients for 6 weeks increased insulin sensitivity and attenuated hepatic inflammation and fibrosis⁵⁰. Two phase III trials involving 3,000 patients from more than 20 countries are upcoming to verify its influence (ClinicalTrials.gov Identifier: NCT02548351, NCT03439254). As exhibited in the interim results of phase III trials, OCA improved hepatic fibrosis with no worsening of NASH compared with placebo. However, OCA has several side effects, like pruritus, gastrointestinal events, and so on⁴⁹. A nonsteroidal FXR agonist, GS-9674, has been exploited to address some of the side effects of OCA. GS-9674 mitigated liver steatosis and hepatic biochemistry in subjects with NASH in a phase II RCT (ClinicalTrials.gov Identifier: NCT02854605). Other FXR agonists, such as LMB763 and LNJ452, with limited side effects, have also been tested in phase II trials (ClinicalTrials.gov Identifier: NCT02913105, NCT02855164).

Fibroblast Growth Factor 19/21 (FGF 19/21) Analog. A peptide hormone FGF19 is released from the intestine after bile acid binding to FXR and regulates bile acid synthesis and lipid metabolism^{51,52}. In a preclinical study, treatment with FGF19 significantly decreased diet-induced hepatic steatosis⁵³. NGM-282 is a recombinant FGF19 with the beneficial metabolic effects of reducing steatosis and lipotoxicity. Furthermore, a phase II study of 166 biopsy-confirmed NASH patients indicated that NGM-282 significantly reduced liver fat content with an acceptable safety profile as well as adverse events, including diarrhea, abdominal pain, and nausea⁵⁴. Another phase II multiple-center study is ongoing to ascertain the safety and effectiveness of NGM282 in histologically confirmed NASH patients (ClinicalTrials.gov Identifier: NCT02443116).

FGF21, a 181-amino acid-secreted protein produced in the liver, enhances glycogen synthesis and ameliorates insulin sensitivity, which was beneficial in treating NASH in rodent models⁵⁵⁻⁵⁷. Due to the short half-life period of wild-type FGF21, the recombinant mutant FGF21, and the conjugation of FGF21 to polyethylene glycol (PEG), has been developed and was tested for its role in NASH. This variant of FGF21 (LY2405319) alleviated inflammation and reversed hepatofibrosis in an animal study of NASH⁵⁸. Notably, a PEGylated FGF21 (BMS-986036) was demonstrated to significantly reduce hepatic fat in NASH patients and had good tolerance in a phase II clinical study⁵⁹. Two phase II trials of BMS-986036 in NASH patients with stage 3 disease are currently

Table 1. Recently Completed and Ongoing Randomized Controlled Trials for NASH.

Agents	Mechanisms	Primary Endpoint(s)	Phase Completed	Patients (n)	Duration	Status	NCT
GS-0976	ACC inhibitor	Overall safety	II	125	Up to 12 weeks plus 30 days	Completed	NCT02856555
Obeticholic acid	FXR agonist	Improvement in liver histology in non-cirrhotic NASH	III	2500	18 months	Recruiting	NCT02548351
Obeticholic acid	FXR agonist	Improvement in fibrosis	III	540	12 months	Recruiting	NCT03439254
GS-9674	FXR agonist	Overall safety	II	125	Up to 24 weeks plus 30 days	Completed	NCT02854605
LMB763	FXR agonist	Adverse event profile and safety; change in transaminase levels	II	100	12 weeks	Recruiting	NCT02913105
LJN452	FXR agonist	Adverse event profile; change in transaminase levels and fat in the liver	II	250	12 weeks	Recruiting	NCT02855164
NGM-282	FGF19 analog	Change in hepatic fat	II	75	24 weeks	Recruiting	NCT024443116
BMS-986036	FGF 21 analog	Improvement in fibrosis	II	160	24 weeks	Recruiting	NCT03486899
BMS-986036	FGF 21 analog	Improvement in fibrosis	II	100	48 weeks	Recruiting	NCT03486912
Elafibranor	PPAR / agonist	Resolution of NASH without worsening fibrosis	III	2000	72 weeks	Recruiting	NCT02704403
MGL-3196	THR agonist	Change in hepatic fat	II	117	12 weeks	Active, not recruiting	NCT02912260
Aramchol	SCD-1 inhibitor	Change in the hepatic fat	II	240	52 weeks	Completed	NCT02279524
Liraglutide	GLP-1 receptor agonist	Improvement in NASH	III	36	12 months	Recruiting	NCT02654665
Cenicriviroc	CCR2/5 antagonist	Improvement in liver histology	III	2000	12 months	Recruiting	NCT03028740
JKB-121	TLR4 antagonist	Change in hepatic fat and improvement in ALT	II	60	24 weeks	Completed	NCT02442687
GS-4997 + Simtuzumab	ASK1 inhibitor, LOXL2 inhibitor	Adverse event profile	II	70	Up to 28 weeks	Completed	NCT02466516
Selonsertib	ASK1 inhibitor	Improvement in fibrosis without worsening NASH	III	800	48 weeks	Active, not recruiting	NCT03053050
GR-MD-02	Galectin-3 inhibitor	Improvement in fibrosis	II	30	16 weeks	Completed	NCT02421094
Emricasan	Caspase inhibitor	Improvement in fibrosis without worsening steatohepatitis	II	330	72 weeks	Active, not recruiting	NCT02686762
GS-9450	Caspase inhibitor	Safety and tolerability	II	110	8 weeks	Completed	NCT00740610

ACC, acetyl-CoA carboxylase; FXR, farnesoid X receptor; FGF19, fibroblast growth factor 19; FGF21, fibroblast growth factor 21; PPAR / , peroxisome proliferator-activated receptor / ; THR , thyroid hormone receptor ; LDL-C, low-density lipoprotein cholesterol; SCD1, stearyl coenzyme a desaturase 1; GLP-1, glucagon-like peptide 1; CCR2/5, C-C motif chemokine receptor 2/5; TLR4, toll-like receptor 4; ALT, alanine transaminase; ASK1, apoptosis signal-regulating kinase 1; LOXL2, lysyl oxidase-like protein 2.

ongoing (ClinicalTrials.gov Identifier: NCT03486899, NCT03486912).

PPAR / Agonist. PPAR activation regulates fatty acid β -oxidation and lipid transport, while PPAR activation results in fatty acid oxidation⁶⁰. Elafibranor (GFT505) is a dual PPAR / agonist that can improve peripheral insulin sensitivity. Treatment of an animal model of NASH demonstrated a decrease in hepatic fat and improvement in hepatic steatosis, inflammation, and fibrosis⁶¹. The antifibrotic effect of GFT-505 was independent of metabolic corrections. Elafibranor also reduced liver enzyme concentrations and had a reassuring safety profile⁶². Recent results from the phase IIb RCT demonstrated that Elafibranor resolved NASH and lowered ALT levels without worsening of fibrosis. It also exhibits beneficial effects on metabolic markers, including improving insulin sensitivity, lowering plasma triglycerides, and increasing high-density lipoprotein cholesterol⁶³. Furthermore, it was well tolerated and thus may be a promising drug candidate for NASH therapy⁶³. A pivotal phase III RESOLVE-IT trial of Elafibranor is currently recruiting patients (ClinicalTrials.gov Identifier: NCT02704403).

Thyroid Hormone Receptor (THR) Agonists. THR is the crucial nuclear receptor for the action of thyroid hormones, especially triiodothyronine (T3), on hepatocytes. It has been confirmed to reduce hepatic lipotoxicity and improve hepatic function by lowering fatty acid accumulation and degeneration⁶⁴. THR agonists have also been shown to induce liver regeneration via stimulation of Wnt/ β -catenin pathway and inducing hepatocyte proliferation, while reducing hepatocellular cancer burden, which could all be beneficial in NASH⁶⁵⁻⁶⁷. A THR agonist prevented hepatic steatosis but impaired insulin sensitivity in high-fat diet-fed rats⁶⁸. In a multicenter study in adults with biopsy-confirmed NASH, a highly selective liver-targeted THR agonist MGL-3196 for 12 weeks significantly decreased hepatic fat relative to placebo⁶⁹. Moreover, VK2809, a liver-targeted THR agonist, was shown to reduce liver triglycerides and microvesicular steatosis in rats and mice⁷⁰. Phase II trials of MGL-3196 and VK2809 are scheduled to begin enrolling patients soon (ClinicalTrials.gov Identifier: NCT02912260, NCT02927184).

Stearoyl Coenzyme A Desaturase 1 (SCD1) Inhibitor. SCD1 is the central enzyme that catalyzes the synthesis of fatty acids and decreases β -oxidation⁷¹. Aramchol, a novel SCD1 inhibitor, reduces hepatic fat content and mitigates steatohepatitis and fibrosis in mice⁷². In a phase II RCT of biopsy-proven NASH and NAFLD subjects, Aramchol given once a day for 3 months reduced hepatic fat with no adverse events⁷³. However, this trial did not verify the effect of Aramchol on hepatic inflammation and fibrosis associated with NASH. In a 52-week phase

IIb RCT of biopsy-proven NASH patients, two doses of Aramchol (400 and 600 mg) significantly reduced hepatic fat and improved histologic features with excellent safety and tolerability (ClinicalTrials.gov Identifier: NCT02279524). A phase III trial with a large sample size should be designed to determine the therapeutic effects of Aramchol.

Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist. GLP-1, first described as a gut-derived hormone generated through the proteolytic processing of proglucagon^{74,75}, has an influence on liver metabolism in NASH^{76,77}. Preclinical studies observed reductions in liver enzymes and oxidative stress accompanied by improvements in liver histology in murine models of NASH after GLP-1 receptor agonist intervention^{78,79}. The GLP-1 receptor agonist liraglutide was reported to ameliorate hepatic inflammation and ballooning in an animal study⁸⁰. In humans, a randomized, placebo-controlled phase II trial showed liraglutide to cause histological resolution of NASH without deterioration of fibrosis⁸¹. It was found to be safe and well tolerated, but extensive, longer duration studies are warranted^{81,82}. A phase III study to compare the therapeutic potency of liraglutide and bariatric surgery in NASH is currently enrolling cases (ClinicalTrials.gov Identifier: NCT02654665).

Targeting Inflammation and Oxidative Stress

C-C Motif Chemokine Receptor 2/5 (CCR2/5) Antagonist. The CCR2/5 chemokine axis recruits immune cells to the liver to initiate an immune response⁸³. The CCR2/5 antagonist Cenicriviroc (CVC) displays anti-inflammatory and antifibrotic activities in preclinical models and may be useful in the treatment of NASH⁸⁴. Presently, its efficacy and safety are being tested in a phase IIb RCT (CENTAUR trial) for treating NASH and hepatic fibrosis. CVC has shown a significant antifibrotic benefit with no worsening of steatohepatitis after 1 year. Compared with placebo, biomarkers of inflammation were significantly reduced after CVC intervention⁸⁵. A phase III study is currently recruiting patients and evaluating the role of CVC for the treatment of NASH (ClinicalTrials.gov Identifier: NCT03028740).

Toll-Like Receptor 4 (TLR4) Antagonist. TLR4 is a crucial mediator of innate immunity and is involved in inflammation and insulin resistance^{86,87}. It has been a potential target for amelioration of hepatic injury, insulin resistance, and progression to NASH in preclinical studies^{88,89}. Notably, the TLR4 antagonist JKB-121 reduced LPS-induced inflammatory liver injury and inhibited hepatic stellate cell activation, supporting JKB-121 as a potential treatment for NASH. However, a phase II RCT of JKB-121 in 65 patients with NASH was completed with unsatisfactory results. Compared to placebo, JKB-121 did not further improve liver fat or ALT and

showed mild drug-related adverse events (ClinicalTrials.gov Identifier: NCT02442687).

Apoptosis Signal-Regulating Kinase 1 (ASK-1) Inhibitor. ASK1 is a member of the MAP3K family and regulates the p38/JNK pathways⁹⁰. ASK1 inhibition improves liver steatosis, inflammation, insulin resistance, and fibrosis in rodent and primate models of NASH^{91–93}, suggesting CASP8, FADD-like apoptosis regulator (CFLAR), and TNF- α -induced protein 3 (TNFAIP3) as potential targets for the treatment of NASH^{94,95}. Selonsertib (GS-4997), which targets ASK1, was assessed in a multicenter phase II trial in which selonsertib was shown to alleviate hepatic fibrosis in NASH patients and those with stage 2 or 3 fibrosis⁹⁶. Therapy using a combination of selonsertib and simtuzumab improved fibrosis with high-dose selonsertib (ClinicalTrials.gov Identifier: NCT02466516). In addition, patient-reported outcomes displayed that selonsertib or selonsertib in combination with simtuzumab lowered hepatic collagen in NASH patients and stages 2–3 liver fibrosis⁹⁷. Selonsertib is now being tested in a phase III trial for the treatment of NASH and F3 fibrosis (ClinicalTrials.gov Identifier: NCT03053050). Unfortunately, the latest report by Gilead shows that selonsertib failed to achieve the main goal of improving liver fibrosis in the phase III trial.

TGF- β -Activated Kinase 1 (TAK1) Inhibitor. TAK1 facilitates the activation of downstream JNK and NF- κ B cascades, promoting the development of NASH⁸⁷. Inhibition of TAK1 activity by deubiquitination or dephosphorylation protected against hepatic steatosis, insulin resistance, and inflammation and is thereby considered to be a therapeutic target for NASH^{98–101}. In animal studies of NASH, specific proteins targeting TAK1, such as cylindromatosis (CYLD), ubiquitin-specific protease 4 (USP4), and dual-specificity phosphatase 14 (DUSP14), have been shown to hinder the progress of NASH^{101–103}. However, no clinical trials have been designed to verify the effects of TAK1 inhibition on NASH.

Galectin-3 Inhibitor. Galectin-3, a β -galactoside-binding animal lectin, is expressed predominantly in immune cells, which regulates the progression of hepatic fibrosis¹⁰⁴. Galactoarabinorhamnogalacturnate (GR-MD-02), a complex carbohydrate-based inhibitor that binds to galectin-3, ameliorated histopathological features of NASH and fibrosis in a preclinical study of NASH¹⁰⁵. Furthermore, GR-MD-02 was safe and well tolerated, as demonstrated by the phase I human study of subjects with histologically confirmed NASH and stage 3 fibrosis¹⁰⁶. Recently, one phase II randomized trial has already completed testing the role of GR-MD-02 in treating NASH patients. However, the results showed no apparent improvement in the levels of noninvasive biomarkers of hepatic inflammation or fibrosis after 16 weeks

of therapy with GR-MD-02 (ClinicalTrials.gov Identifier: NCT02421094).

Caspase Inhibitor. Caspases are a class of enzymes that play a critical role in executing apoptotic pathways or programmed cell death. Emricasan (IDN-6556), a currently available irreversible pancaspase inhibitor, has shown an influence on improving NAS and fibrosis in preclinical trials¹⁰⁷. In a phase II study, 38 subjects with proven NAFLD/NASH were randomly assigned to receive Emricasan 25 mg twice a day or placebo for 28 days with a primary result of reduction in ALT and biomarkers¹⁰⁸. Recently, a phase IIb study of Emricasan will begin enrolling cases soon (ClinicalTrials.gov Identifier: NCT02686762). Another caspase inhibitor, GS-9450, can act selectively on caspases 1, 8, and 9. As exhibited in a phase II, double-blind trial, GS-9450 significantly reduced ALT levels in patients with NASH¹⁰⁹. The safety and efficacy of GS-9450 for NASH need to be assessed in larger-scale clinical trials.

CHALLENGES IMPEDING TRANSLATION FROM BENCH TO BEDSIDE IN DRUG DISCOVERY FOR NASH

Drug development for NASH requires clear mechanisms, appropriate animal models, progressive clinical trials, convenient efficacy evaluation, and follow-up methods. Many challenges impeding the translation from bench to bedside remain in this drug discovery process. The pathogenesis of NASH has not been entirely elucidated and has been debated for a long time, which is one of the bottlenecks in drug development. The “multiple-parallel hit” hypothesis was recently proposed, providing a more adequate explanation of how fatty acids and their metabolites promote NASH through multiple sequential or parallel cytotoxic pathways¹¹⁰. The pathogenesis of human NASH involves varied molecular pathways and complex progression with a dynamic bidirectional nature, which is unlikely to be the same in all patients, raising concern about individual differences.

The perfect animal model that mimics the pathophysiology of NASH and displays the most clinical characteristics of human disease as closely as possible does not exist, further increasing the difficulty in identifying and validating potential drug targets for human NASH. Many species, including mice, rabbits, pigs, and monkeys, are used to develop models with a liver phenotype resembling human NASH, and each has its advantages and disadvantages¹¹¹. Recently, monkeys have been recommended as models of NASH due to similarities in liver anatomy, physiology, metabolism, and genetics to humans^{112,113}. Monkey breeding has specific disadvantages including sophisticated genetic methods, housing, cost, and logistics. Moreover, the ideal pharmacodynamics of drugs

in animal models do not necessarily replicate in human NASH.

Because of the slow progression to clinically significant outcomes in NASH, drug development has been delayed, and the potential time to market for drugs has been extended. The use of optimal surrogate endpoints for clinical trials in NASH is imperative for evaluating pharmacologic agents¹¹⁴. For purposes of accelerated approval, the surrogate endpoints used by the FDA can be achieved in a reasonably short timeframe. Biomarkers of NASH are helpful for the diagnosis, monitoring, and prognosis of disease progression and evaluation of the effects of new regimens, which is urgent in the field of NASH. In addition, existing methods of pharmacodynamic evaluation and follow-up are still insufficient to assess NASH progression and regression for drug development.

PROSPECTIVE AND FUTURE

Currently, no FDA-approved drug is available to treat NASH. Lifestyle modification rarely leads to the resolution of NASH, while bariatric surgery can resolve NASH but is just recommended for morbidly obese patients with NASH. Many efforts have been made to develop pharmacotherapies based on the core mechanism of NASH, and some agents have entered phase III favorably. Encouragingly, promising results have been obtained for some medications, including FXR agonists, PPAR- / agonists, GLP-1 agonists, CCR2/5 chemokine receptor antagonists, ASK-1 inhibitors, galectin-3 inhibitors, and caspase inhibitors. However, these drugs are still investigative and experimental. None of these experimental medicines has a perfect function of improving all histological features of NASH and reversing NASH with no drug-related adverse events in the existing clinical trials. Long-term effects and safety on NASH and liver-related mortality and morbidity should be tested in more clinical trials, particularly given concerns about the potential adverse events of some drugs. In the coming years, it is expected that some of these agents alone or in combination will provide the optimal outcomes and new treatment options for NASH patients. Furthermore, improved animal models and scientific research are needed to identify the complete pathogenesis and find new targets for therapy, while specific markers, optimized clinical trial design, suitable surrogate endpoints, and follow-up investigation are required for further drug development.

ACKNOWLEDGMENTS: *This work was supported by grants from the National Science Fund for Distinguished Young Scholars (No. 81425005; H.L.), the Key Project of the National Natural Science Foundation (Nos. 81330005 and 81630011; H.L.), the Major Research Plan of the National Natural Science Foundation of China (Nos. 1729303 and 91639304; H.L.), the Creative Groups Project of Hubei Province (No. 2016CFA010; H.L.), the National Key R&D Program of China (No.*

2016YFF0101504; Z.-G.S.), and the National Natural Science Foundation of China (No. 81770053; Z.-G.S.).

REFERENCES

1. Bellentani S. The epidemiology of non-alcoholic fatty liver disease. *Liver Int.* 2017;37(Suppl 1):81–4.
2. Wong RJ, Liu B, Bhuket T. Significant burden of non-alcoholic fatty liver disease with advanced fibrosis in the US: A cross-sectional analysis of 2011–2014 National Health and Nutrition Examination Survey. *Aliment Pharmacol Ther.* 2017;46(10):974–80.
3. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 2016;64(1):73–84.
4. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. *Gastroenterology* 2015;148(3):547–55.
5. Zhang XJ, She ZG, Li H. Time to step-up the fight against NAFLD. *Hepatology* 2018;67(6):2068–71.
6. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol.* 2018; 15(1):11–20.
7. Younossi ZM. Non-alcoholic fatty liver disease—A global public health perspective. *J Hepatol.* 2019;70(3):531–44.
8. Younossi Z, Tacke F, Arrese M, et al. Global perspectives on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. *Hepatology* 2019;69(6):2672–82.
9. Romero-Gomez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. *J Hepatol.* 2017;67(4):829–46.
10. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. *Cell Metab.* 2016;23(4):591–601.
11. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. *Gastroenterology* 2015;149(2):367–78.e5.
12. Oh S, Shida T, Yamagishi K, et al. Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: A retrospective study. *Hepatology* 2015;61(4):1205–15.
13. Vilar Gomez E, Rodriguez De Miranda A, Gra Oramas B, et al. Clinical trial: A nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. *Aliment Pharmacol Ther.* 2009;30(10):999–1009.
14. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on non-alcoholic steatohepatitis. *Hepatology* 2010;51(1):121–9.
15. Wong VW, Chan RS, Wong GL, et al. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial. *J Hepatol.* 2013;59(3):536–42.
16. Musso G, Gambino R, De Michieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. *Hepatology* 2003;37(4):909–16.
17. Jeyapal S, Kona SR, Mullanpudi SV, Putcha UK, Gurumurthy P, Ibrahim A. Substitution of linoleic acid

- with alpha-linolenic acid or long chain n-3 polyunsaturated fatty acid prevents Western diet induced non-alcoholic steatohepatitis. *Sci Rep.* 2018;8(1):10953.
18. European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol.* 2016;64(6):1388–402.
 19. Zelber-Sagi S, Salomone F, Mlynarsky L. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms. *Liver Int.* 2017;37(7):936–49.
 20. Della Corte C, Mosca A, Vania A, Alterio A, Iasevoli S, Nobili V. Good adherence to the Mediterranean diet reduces the risk for NASH and diabetes in pediatric patients with obesity: The results of an Italian Study. *Nutrition* 2017;39–40:8–14.
 21. Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. *N Engl J Med.* 2017;377(21):2063–72.
 22. Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. *Hepatology* 2012;55(2):429–36.
 23. Abdel Monem SM. Probiotic therapy in patients with non-alcoholic steatohepatitis in Zagazig University Hospitals. *Euroasian J Hepatogastroenterol.* 2017;7(1):101–6.
 24. Manzhali E, Virchenko O, Falalyeyeva T, Beregova T, Stremmel W. Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: A pilot trial. *J Dig Dis.* 2017;18(12):698–703.
 25. Kwak MS, Kim D. Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activity. *Korean J Intern Med.* 2018;33(1):64–74.
 26. van der Windt DJ, Sud V, Zhang H, Tsung A, Huang H. The effects of physical exercise on fatty liver disease. *Gene Expr.* 2018;18(2):89–101.
 27. Issa D, Wattacheril J, Sanyal AJ. Treatment options for nonalcoholic steatohepatitis—A safety evaluation. *Expert Opin Drug Saf.* 2017;16(8):903–13.
 28. Yu HH, Hsieh MC, Wu SY, Sy ED, Shan YS. Effects of duodenal-jejunal bypass surgery in ameliorating nonalcoholic steatohepatitis in diet-induced obese rats. *Diabetes Metab Syndr Obes.* 2019;12:149–59.
 29. Lassailly G, Caiazzo R, Buob D, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. *Gastroenterology* 2015;149(2):379–88.
 30. Schneck AS, Anty R, Patouraux S, et al. Roux-En Y gastric bypass results in long-term remission of hepatocyte apoptosis and hepatic histological features of non-alcoholic steatohepatitis. *Front Physiol.* 2016;7:344.
 31. Tan CH, Al-Kalifah N, Ser KH, Lee YC, Chen JC, Lee WJ. Long-term effect of bariatric surgery on resolution of nonalcoholic steatohepatitis (NASH): An external validation and application of a clinical NASH score. *Surg Obes Relat Dis.* 2018;14(10):1600–6.
 32. Fan JG, Wei L, Zhuang H, National Workshop on Fatty L, Alcoholic Liver Disease CSoHCMA, Fatty Liver Disease Expert Committee CMDA. Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China). *J Dig Dis.* 2019;20(4):163–73.
 33. Chung MY, Yeung SF, Park HJ, Volek JS, Bruno RS. Dietary alpha- and gamma-tocopherol supplementation attenuates lipopolysaccharide-induced oxidative stress and inflammatory-related responses in an obese mouse model of nonalcoholic steatohepatitis. *J Nutr Biochem.* 2010;21(12):1200–6.
 34. Sanyal AJ, Mofrad PS, Contos MJ, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. *Clin Gastroenterol Hepatol.* 2004;2(12):1107–15.
 35. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study. *J Pediatr.* 2000;136(6):734–8.
 36. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. *Am J Gastroenterol.* 2003;98(11):2485–90.
 37. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *N Engl J Med.* 2010;362(18):1675–85.
 38. Klein EA, Thompson IM, Jr., Tangen CM, et al. Vitamin E and the risk of prostate cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). *JAMA* 2011;306(14):1549–56.
 39. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: Pathophysiology and clinical implications. *Gastroenterology* 2012;142(4):711–25.e16.
 40. Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. *Gastroenterology* 2008;135(4):1176–84.
 41. Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial. *Ann Intern Med.* 2016;165(5):305–15.
 42. Foster DW. Malonyl-CoA: The regulator of fatty acid synthesis and oxidation. *J Clin Invest.* 2012;122(6):1958–9.
 43. Lawitz EJ, Coste A, Poordad F, et al. Acetyl-CoA carboxylase inhibitor GS-0976 for 12 weeks reduces hepatic de novo lipogenesis and steatosis in patients with non-alcoholic steatohepatitis. *Clin Gastroenterol Hepatol.* 2018;16(12):1983–91.e83.
 44. Harriman G, Greenwood J, Bhat S, et al. Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats. *Proc Natl Acad Sci USA* 2016;113(13):E1796–805.
 45. Kim CW, Addy C, Kusunoki J, et al. Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: A bedside to bench investigation. *Cell Metab.* 2017;26(3):576.
 46. Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. *Drug Discov Today* 2012;17(17–18):988–97.
 47. Chiang JYL, Ferrell JM. Bile acid metabolism in liver pathobiology. *Gene Expr.* 2018;18(2):71–87.
 48. Cipriani S, Mencarelli A, Palladino G, Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. *J Lipid Res.* 2010;51(4):771–84.
 49. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial. *Lancet* 2015;385(9972):956–65.

50. Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. *Gastroenterology* 2013;145(3):574–82.e71.
51. Nies VJ, Sancar G, Liu W, et al. Fibroblast growth factor signaling in metabolic regulation. *Front Endocrinol. (Lausanne)* 2015;6:193.
52. You M, Zhou Z, Daniels M, Jogasuria A. Endocrine adiponectin–FGF15/19 axis in ethanol-induced inflammation and alcoholic liver injury. *Gene Expr.* 2018;18(2):103–13.
53. Alvarez-Sola G, Uriarte I, Latasa MU, et al. Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: Development of an FGF19-based chimeric molecule to promote fatty liver regeneration. *Gut* 2017;66(10):1818–28.
54. Harrison SA, Rinella ME, Abdelmalek MF, et al. NGM282 for treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet* 2018;391(10126):1174–85.
55. Cicione C, Degirolamo C, Moschetta A. Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver. *Hepatology* 2012;56(6):2404–11.
56. Zhang F, Yu L, Lin X, et al. Minireview: Roles of fibroblast growth factors 19 and 21 in metabolic regulation and chronic diseases. *Mol Endocrinol.* 2015;29(10):1400–13.
57. Markan KR, Naber MC, Ameka MK, et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. *Diabetes* 2014;63(12):4057–63.
58. Lee JH, Kang YE, Chang JY, et al. An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function. *Am J Transl Res.* 2016;8(11):4750–63.
59. Sanyal A, Charles ED, Neuschwander-Tetri BA, et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: A randomised, double-blind, placebo-controlled, phase 2a trial. *Lancet* 2019;392(10165):2705–17.
60. Barbara M, Scott A, Alkhoury N. New insights into genetic predisposition and novel therapeutic targets for nonalcoholic fatty liver disease. *Hepatobiliary Surg Nutr.* 2018;7(5):372–81.
61. Staels B, Rubenstrunk A, Noel B, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. *Hepatology* 2013;58(6):1941–52.
62. Cariou B, Hanf R, Lambert-Porcheron S, et al. Dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. *Diabetes Care* 2013;36(10):2923–30.
63. Ratzu V, Harrison SA, Francque S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. *Gastroenterology* 2016;150(5):1147–59. e45.
64. Kelly MJ, Pietranico-Cole S, Larigan JD, et al. Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a highly selective thyroid hormone receptor beta agonist in clinical trials for the treatment of dyslipidemia. *J Med Chem.* 2014;57(10):3912–23.
65. Puliga E, Min Q, Tao J, et al. Thyroid hormone receptor-beta agonist GC-1 inhibits met-beta-catenin-driven hepatocellular cancer. *Am J Pathol.* 2017;187(11):2473–85.
66. Alvarado TF, Puliga E, Preziosi M, et al. Thyroid hormone receptor beta agonist induces beta-catenin-dependent hepatocyte proliferation in mice: Implications in hepatic regeneration. *Gene Expr.* 2016;17(1):19–34.
67. Fanti M, Singh S, Ledda-Columbano GM, Columbano A, Monga SP. Tri-iodothyronine induces hepatocyte proliferation by protein kinase A-dependent beta-catenin activation in rodents. *Hepatology* 2014;59(6):2309–20.
68. Vatner DF, Weismann D, Beddow SA, et al. Thyroid hormone receptor-beta agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways. *Am J Physiol Endocrinol Metab.* 2013;305(1):E89–100.
69. Harrison S, Moussa S, Bashir M, Alkhoury N. MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks the primary endpoint in a 36 week serial liver biopsy study. *J Hepatol.* 2018;68:S38.
70. Cable EE, Finn PD, Stebbins JW, et al. Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. *Hepatology* 2009;49(2):407–17.
71. Issandou M, Bouillot A, Brusq JM, et al. Pharmacological inhibition of stearoyl-CoA desaturase 1 improves insulin sensitivity in insulin-resistant rat models. *Eur J Pharmacol.* 2009;618(1–3):28–36.
72. Iruarrizaga-Lejarreta M, Varela-Rey M, Fernandez-Ramos D, et al. Role of Aramchol in steatohepatitis and fibrosis in mice. *Hepatol Commun.* 2017;1(9):911–27.
73. Safadi R, Konikoff FM, Mahamid M, et al. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol.* 2014;12(12):2085–91.e2081.
74. Salehi M, Vahl TP, D'Alessio DA. Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion. *J Clin Endocrinol Metab.* 2008;93(12):4909–16.
75. Mojsov S, Weir GC, Habener JF. Insulinotropin: Glucagon-like peptide I (7–37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. *J Clin Invest.* 1987;79(2):616–9.
76. Bifari F, Manfrini R, Dei Cas M, et al. Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). *Pharmacol Res.* 2018;137:219–29.
77. Armstrong MJ, Hull D, Guo K, et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. *J Hepatol.* 2016;64(2):399–408.
78. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. *Hepatology* 2006;43(1):173–81.
79. Trevaskis JL, Griffin PS, Wittmer C, et al. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. *Am J Physiol Gastrointest Liver Physiol.* 2012;302(8):G762–72.
80. Ipsen DH, Rolin B, Rakipovski G, et al. Liraglutide decreases hepatic inflammation and injury in advanced

- lean non-alcoholic steatohepatitis. *Basic Clin Pharmacol Toxicol*. 2018;123(6):704–13.
81. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study. *Lancet* 2016; 387(10019):679–90.
 82. Armstrong MJ, Houlihan DD, Rowe IA, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: Individual patient data meta-analysis of the LEAD program. *Aliment Pharmacol Ther*. 2013;37(2):234–42.
 83. Krenkel O, Tacke F. Liver macrophages in tissue homeostasis and disease. *Nat Rev Immunol*. 2017;17(5):306–21.
 84. Lefebvre E, Moyle G, Reshef R, et al. Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis. *PLoS One* 2016;11(6):e0158156.
 85. Friedman SL, Ratziu V, Harrison SA, et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. *Hepatology* 2018;67(5):1754–67.
 86. Xu M, Liu PP, Li H. Innate immune signaling and its role in metabolic and cardiovascular diseases. *Physiol Rev*. 2019;99(1):893–948.
 87. Cai J, Zhang XJ, Li H. Role of innate immune signaling in non-alcoholic fatty liver disease. *Trends Endocrinol Metab*. 2018;29(10):712–22.
 88. Zhao GN, Zhang P, Gong J, et al. Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4. *Nat Med*. 2017;23(6):742–52.
 89. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, et al. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. *Diabetes* 2007;56(8):1986–98.
 90. Cai J, Xu M, Zhang X, Li H. Innate immune signaling in nonalcoholic fatty liver disease and cardiovascular diseases. *Annu Rev Pathol*. 2019;14:153–84.
 91. Xiang M, Wang PX, Wang AB, et al. Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis. *J Hepatol*. 2016;64(6):1365–77.
 92. Zhang P, Wang PX, Zhao LP, et al. The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis. *Nat Med*. 2018;24(1):84–94.
 93. Wang PX, Ji YX, Zhang XJ, et al. Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates. *Nat Med*. 2017;23(4):439–49.
 94. Kovalic AJ, Satapathy SK, Chalasani N. Targeting incretin hormones and the ASK-1 pathway as therapeutic options in the treatment of non-alcoholic steatohepatitis. *Hepatol Int*. 2018;12(2):97–106.
 95. Schuster S, Feldstein AE. NASH: Novel therapeutic strategies targeting ASK1 in NASH. *Nat Rev Gastroenterol Hepatol*. 2017;14(6):329–30.
 96. Loomba R, Lawitz E, Mantry PS, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. *Hepatology* 2018; 67(2):549–59.
 97. Younossi ZM, Stepanova M, Lawitz E, et al. Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. *Liver Int*. 2018;38(10):1849–59.
 98. Wang PX, Zhang XJ, Luo P, et al. Hepatocyte TRAF3 promotes liver steatosis and systemic insulin resistance through targeting TAK1-dependent signalling. *Nat Commun*. 2016;7:10592.
 99. An S, Zhao LP, Shen LJ, et al. USP18 protects against hepatic steatosis and insulin resistance through its deubiquitinating activity. *Hepatology* 2017;66(6):1866–84.
 100. Yan FJ, Zhang XJ, Wang WX, et al. The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis. *Hepatology* 2017;65(5):1492–511.
 101. Wang S, Yan ZZ, Yang X, et al. Hepatocyte DUSP14 maintains metabolic homeostasis and suppresses inflammation in the liver. *Hepatology* 2018;67(4):1320–38.
 102. Ji YX, Huang Z, Yang X, et al. The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis. *Nat Med*. 2018;24(2):213–23.
 103. Zhao Y, Gao L, Xu L, et al. Ubiquitin-specific protease 4 is an endogenous negative regulator of metabolic dysfunctions in nonalcoholic fatty liver disease. *Hepatology* 2018. [Epub ahead of print]
 104. Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. *Proc Natl Acad Sci USA* 2006;103(13):5060–5.
 105. Traber PG, Zomer E. Therapy of experimental NASH and fibrosis with galectin inhibitors. *PLoS One* 2013;8(12):e83481.
 106. Harrison SA, Marri SR, Chalasani N, et al. Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis. *Aliment Pharmacol Ther*. 2016;44(11–12):1183–98.
 107. Barreiro FJ, Holod S, Finocchietto PV, et al. The pancaspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. *Liver Int*. 2015;35(3):953–66.
 108. Shiffman M, Freilich B, Vuppalanchi R, et al. Randomised clinical trial: Emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease. *Aliment Pharmacol Ther*. 2019;49(1):64–73.
 109. Ratziu V, Sheikh MY, Sanyal AJ, et al. A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. *Hepatology* 2012;55(2):419–28.
 110. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). *Metabolism* 2016;65(8):1038–48.
 111. Jahn D, Kircher S, Hermanns HM, Geier A. Animal models of NAFLD from a hepatologist's point of view. *Biochim Biophys Acta Mol Basis Dis*. 2019;1865(5):943–53.
 112. Cai J, Zhang XJ, Li H. Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. *Med Res Rev*. 2019;39(1):328–48.
 113. Nagarajan P, Venkatesan R, Kumar M, Usmani A, Majumdar SS. *Macaca radiata* (bonnet monkey): A spontaneous model of nonalcoholic fatty liver disease. *Liver Int*. 2008;28(6):856–64.
 114. Hannah WN, Jr., Torres DM, Harrison SA. Nonalcoholic steatohepatitis and endpoints in clinical trials. *Gastroenterol Hepatol*, (N Y) 2016;12(12):756–63.